22
total announcements
506197.BO · 15 min delayed
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has published a newspaper advertisement regarding the extension of the special window for re-lodging transfer requests of physical shares, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd submitted newspaper publications for a postal ballot notice as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has announced a postal ballot notice for the appointment of Mr. Santosh Parab as a Non-Executive and Non-Independent Director of the Company. The voting period will commence from August 21, 2026, and ends on September 19, 2026.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has published the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd granted 3,20,000 stock options under Employee Stock Options Plan 2019 to eligible employees, with vesting in 4 instalments over 48 months, and a lock-in period of 6 months from allotment of equity shares.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with the company reporting a net profit of ₹4,791.83 crore and a total income of ₹3,797.13 crore.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the approval of the appointment of Mr. Santosh Parab as a Director of the Company.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has informed that the ESOP Allotment Committee has approved the allotment of 31,250 equity shares to eligible employees under the Employee Stock Option Plan 2019, increasing the issued and paid-up share capital from 10,62,43,973 to 10,62,75,222 shares.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Life Insurance Corporation of India, indicating a potential substantial acquisition of shares.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has scheduled a Board Meeting on August 12, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has received a pre-offer advertisement from SBI Capital Markets Ltd regarding an open offer for acquisition of up to 26.00% of the company's expanded voting share capital by Anupam Rasayan India Ltd and Mates Visa Consultancy Private Ltd.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has announced the resignation of Mr. Sachin Saboo, General Manager – Regulatory and Clinical, citing his intent to move forward in a direction that aligns more closely with his professional aspirations. The company has accepted his resignation, effective July 24, 2026.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has announced the publication of the recommendation of the Committee of Independent Directors regarding the open offer made by Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited to acquire up to 26% of the company's expanded voting share capital at a price of INR 299 per share.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has announced that it will transfer unclaimed dividends and corresponding shares to the Investor Education and Protection Fund (IEPF) Authority as per the Companies Act, 2013 and IEPF Rules. Shareholders who have not claimed dividends for 7 years or more will have their shares transferred to IEPF. Shareholders can prevent this by submitting a written request with required documents to the RTA by October 27, 2026.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has received an open offer from Anupam Rasayan India Ltd and Mates Visa Consultancy Pvt Ltd to acquire up to 26% of the company's expanded voting share capital at INR 299 per share, aggregating to INR 829 crore. The Committee of Independent Directors has recommended the open offer in compliance with SEBI regulations.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Clarus Capital I & Others.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has published a notice in newspapers regarding the transfer of unclaimed final dividend 2018-2019 and its corresponding equity shares to the Investor Education and Protection Fund (IEPF) Authority, as per the Companies Act, 2013 and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has received a Letter of Offer dated July 18, 2026 from SBI Capital Markets Limited, the Manager to the Open Offer appointed by Anupam Rasayan India Limited along with PAC, for the acquisition of up to 2,77,26,848 (Two Crore Seventy-Seven Lakh Twenty-Six Thousand Eight Hundred Forty-Eight) fully paid-up equity shares of face value of ₹ 1 (Indian Rupee One) each, representing 26.00% (Twenty-Six per cent) of the Expanded Voting Share Capital from the eligible public shareholders of the Target Company.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has announced the record date for the payment of the final dividend for the financial year ended March 31, 2026. The record date for eligible shareholders is Wednesday, July 08, 2026. The company's register of members and share transfer books will be closed from July 09 to July 15, 2026. The 41st Annual General Meeting will also be held on July 15, 2026, where the dividend is expected to be approved and subsequently distributed by August 14, 2026.
Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd has announced the book closure period from July 9, 2026, to July 15, 2026, for its 41st Annual General Meeting (AGM) and for the purpose of paying the final dividend for the financial year ended March 31, 2026. The record date for the final dividend is July 8, 2026. The dividend, if approved by members at the AGM on July 15, 2026, will be distributed to shareholders on or before August 14, 2026.